Zhang Zhen, Li Bao-Ying, Li Xiao-Li, Cheng Mei, Yu Fei, Lu Wei-da, Cai Qian, Wang Jun-Fu, Zhou Rui-Hai, Gao Hai-Qing, Shen Lin
Department of Geriatrics, Qi-Lu Hospital of Shandong University, Key Laboratory of Cardiovascular Proteomics of Shandong Province, People's Republic of China.
Biochim Biophys Acta. 2013 Jun;1832(6):805-16. doi: 10.1016/j.bbadis.2013.02.022. Epub 2013 Mar 6.
Diabetic nephropathy, as a severe microvascular complication of diabetic mellitus, has become the leading cause of end-stage renal diseases. However, no effective therapeutic strategy has been developed to prevent renal damage progression to end stage renal disease. Hence, the present study evaluated the protective effects of grape seed procyanidin B2 (GSPB2) and explored its molecular targets underlying diabetic nephropathy by a comprehensive quantitative proteomic analysis in db/db mice. Here, we found that oral administration of GSPB2 significantly attenuated the renal dysfunction and pathological changes in db/db mice. Proteome analysis by isobaric tags for relative and absolute quantification (iTRAQ) identified 53 down-regulated and 60 up-regulated proteins after treatment with GSPB2 in db/db mice. Western blot analysis confirmed that milk fat globule EGF-8 (MFG-E8) was significantly up-regulated in diabetic kidney. MFG-E8 silencing by transfection of MFG-E8 shRNA improved renal histological lesions by inhibiting phosphorylation of extracellular signal-regulated kinase1/2 (ERK1⁄2), Akt and glycogen synthase kinase-3beta (GSK-3β) in kidneys of db/db mice. In contrast, over-expression of MFG-E8 by injection of recombinant MFG-E8 resulted in the opposite effects. GSPB2 treatment significantly decreased protein levels of MFG-E8, phospho-ERK1/2, phospho-Akt, and phospho-GSK-3β in the kidneys of db/db mice. These findings yield insights into the pathogenesis of diabetic nephropathy, revealing MFG-E8 as a new therapeutic target and indicating GSPB2 as a prospective therapy by down-regulation of MFG-E8, along with ERK1/2, Akt and GSK-3β signaling pathway.
糖尿病肾病作为糖尿病严重的微血管并发症,已成为终末期肾病的主要病因。然而,尚未开发出有效的治疗策略来预防肾脏损伤进展至终末期肾病。因此,本研究通过对db/db小鼠进行全面的定量蛋白质组学分析,评估了葡萄籽原花青素B2(GSPB2)的保护作用作用作用其对糖尿病肾病潜在的分子靶点。在此,我们发现口服GSPB2可显著减轻db/db小鼠的肾功能障碍和病理变化。通过相对和绝对定量的等压标签(iTRAQ)进行蛋白质组分析,确定了db/db小鼠在接受GSPB2治疗后有53种下调蛋白和60种上调蛋白。蛋白质免疫印迹分析证实,乳脂肪球表皮生长因子8(MFG-E8)在糖尿病肾脏中显著上调。通过转染MFG-E8 shRNA沉默MFG-E8可抑制db/db小鼠肾脏中细胞外信号调节激酶1/2(ERK1⁄2)、Akt和糖原合酶激酶-3β(GSK-3β)的磷酸化,从而改善肾脏组织学损伤。相反,注射重组MFG-E8过表达MFG-E8则产生相反的效果。GSPB2治疗显著降低了db/db小鼠肾脏中MFG-E8、磷酸化ERK1/2、磷酸化Akt和磷酸化GSK-3β的蛋白水平。这些发现为糖尿病肾病的发病机制提供了见解,揭示MFG-E8是一个新的治疗靶点,并表明GSPB2通过下调MFG-E8以及ERK1/2、Akt和GSK-3β信号通路是一种有前景的治疗方法。